Form 8-K

8-K — Apogee Therapeutics, Inc.

Accession: 0001104659-26-066575

Filed: 2026-05-27

Period: 2026-05-26

CIK: 0001974640

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Entry into a Material Definitive Agreement

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2615568d2_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2615568d2_ex99-1.htm)

GRAPHIC (tm2615568d2_ex99-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2615568d2_8k.htm · Sequence: 1

false

0001974640

2026-05-26

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13

or 15(d)

of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

May 26, 2026

Apogee

Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its

Charter)

Delaware

001-41740

93-4958665

(State

of Incorporation or

Organization)

(Commission File Number)

(I.R.S.

Employer Identification

No.)

221

Crescent Street, Building 17,

Suite 102b,

Waltham,

MA, 02453

(Address of Principal

Executive Offices, including Zip Code)

(650)

394-5230

(Registrant’s telephone

number, including area code)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant

to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common

Stock, par value $0.00001 per share

APGE

The

Nasdaq Global

Market

Indicate by check mark whether the registrant is

an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01 Entry into a Material Definitive Agreement.

Revenue Participation Right Purchase and Sale Agreement

May 26, 2026 (the “Effective Date”), Apogee Therapeutics, Inc. (the “Company”) entered into a revenue participation

right purchase and sale agreement (the “Revenue Share Agreement”) with Annapurna Aggregator L.P., an affiliate of funds managed

by Blackstone Life Sciences (“BXLS”).

Pursuant

to the Revenue Share Agreement, in exchange for an upfront payment of $100.0 million (the “Tranche 1 Funding”), BXLS purchased

from the Company the right to receive tiered revenue share payments (the “Revenue Share Payments”) with respect to annual

worldwide net product sales (“Net Sales”) of the Company’s anti-IL-13 antibody, zumilokibart (APG777) (“zumilokibart”).

In addition, under the Revenue Share Agreement:

(i) BXLS will purchase additional Revenue Share Payments from the Company

in exchange for a payment of $100.0 million (the “Tranche 2 Funding”), upon the occurrence of full enrollment of patients

in both of the Company’s planned registrational monotherapy Phase 3 clinical trials of zumilokibart in patients with atopic dermatitis

(“AD”), coded by the Company as APG777-301 and APG777-302 (the “Zumilokibart Phase 3 Clinical Trials”);

(ii) BXLS will purchase additional Revenue Share Payments from the

Company in exchange for a payment of $200.0 million (the “Tranche 3 Funding”), upon the occurrence of positive data readouts

from the Zumilokibart Phase 3 Clinical Trials meeting agreed upon endpoints with statistical significance; and

(iii) BXLS will purchase additional Revenue Share Payments from the

Company in exchange for a payment (the “Tranche 4 Funding”) of, at the Company’s election, between $250.0 million and

up to $400.0 million (“Tranche 4 Maximum Purchase Price”), upon zumilokibart’s receipt of marketing approval from the

U.S. Food and Drug Administration for the treatment of AD on or prior to December 31, 2030 (the “Tranche 4 Trigger”).

The Revenue Share Payments are based on a tiered percentage of aggregate

annual Net Sales of zumilokibart (“Annual Aggregate Product Net Sales”). Under the Revenue Share Agreement, the revenue percentage

payable to BXLS is the sum of (a) the base revenue percentage (the “Base Revenue Percentage”) and (b) the tranche 4 revenue

percentage (the “Tranche 4 Revenue Percentage” and, together with the Base Revenue Percentage, the “Revenue Percentages”),

which applies only from and after the Tranche 4 Funding.

The table below summarizes the Revenue Percentages payable to BXLS,

based on the tiers of Annual Aggregate Product Net Sales. The Base Revenue Percentage shown reflects the rate applicable after receipt

of the Tranche 1 Funding; this rate would double upon receipt of the Tranche 2 Funding, and double again upon receipt of the Tranche 3

Funding. The Tranche 4 Revenue Percentage is subject to proportional adjustment if the Tranche 4 Funding is less than the Tranche 4 Maximum

Purchase Price:

Annual Aggregate Product Net Sales

Base Revenue

Percentage

Tranche 4 Revenue

Percentage

Maximum Revenue

Percentage

Up to and including $5 billion (“Tier 1”)

0.9375 %

2.50 %

3.4375 %

In excess of $5 billion but less than or equal to $8 billion

0.25 %

0.00 %

0.25 %

The

Tranche 4 Revenue Percentage is subject to a cap of $1.0 billion in aggregate Tranche 4-related Revenue Share Payments to BXLS,

after which the Tranche 4 Revenue Percentage for Tier 1 decreases to 0.00%.

The Revenue Share Payments will be payable during a term commencing

on the date of the first commercial sale of zumilokibart and ending on the fifteenth (15th) anniversary of the date of receipt of marketing

approval for zumilokibart.

If the Company consummates a change of control with a third party,

the Company will be required to pay a certain specified amount to BXLS. Such amount will be credited against future Revenue Share Payments

otherwise payable to BXLS following the consummation of the change of control.

In the alternative, at any time after the Company enters into a definitive

agreement for a change of control, in lieu of the required payment above, the Company will have the option to pay certain specified amounts

to BXLS to buy down a certain percentage of future Revenue Share Payments, if exercised on or prior to the 180-day anniversary of the

Effective Date, or on or prior to December 31, 2030 (each, a “Buy-Back Option”). If the Company exercises a Buy-Back Option,

the Revenue Percentage will be adjusted downward in accordance with the Revenue Share Agreement, and if the Buy-Back Option is exercised

prior to the Tranche 4 Trigger, BXLS will no longer be obligated to pay the Tranche 4 Funding, and in such case the Tranche 4 Revenue

Percentages across all tiers will be 0.00%.

Under the Revenue Share Agreement, for the purposes of providing additional assurance to BXLS, including in the event of a recharacterization, the Company has granted BXLS a backup security interest in, among other things, the revenue participation right, the

Revenue Share Payments, and the Company’s intellectual property and other product rights related to zumilokibart. This backup

security interest will terminate upon the later of (a) a change of control with a permitted transferee and (b) BXLS’s receipt

of the applicable change of control payment.

The Company and BXLS also agree to negotiate in good faith a debt financing

of up to $500.0 million upon mutual agreement of the parties.

The Revenue Share Agreement contains customary representations, warranties

and indemnities of the Company and BXLS, and customary covenants on the part of the Company.

The foregoing description of the Revenue Share Agreement does not purport

to be complete and is qualified in its entirety by reference to the full text of the Revenue Share Agreement, a copy of which will be

filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2026 with the Securities and

Exchange Commission.

Item 7.01 Regulation FD Disclosure.

Press Release

On May 27, 2026, the Company issued a press release announcing the

Revenue Share Agreement.

Supplemental Financial Information

As a result of entering into the transactions described in Item 1.01

of this Current Report on Form 8-K (this “Report”), the Company is removing its cash runway end date guidance.

A copy of the press release is furnished as Exhibit 99.1 to this Report

and is incorporated by reference herein. The information furnished under this Item 7.01, including Exhibit 99.1 to this Report, is furnished

under Item 7.01 of this Report and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange

Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed

incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation

language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

EXHIBIT INDEX

Exhibit

No.

Description

99.1

Press

Release, dated May 27, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Apogee Therapeutics, Inc.

Date: May 27, 2026

By:

/s/ Michael Henderson, M.D.

Michael Henderson, M.D.

Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2615568d2_ex99-1.htm · Sequence: 2

Exhibit 99.1

Apogee Therapeutics Announces $1.3 Billion

Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

Up to $1.3 billion in flexible, non-dilutive

capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt

Combined with company's current total cash

of $1.3 billion, this transaction positions Apogee to achieve a self-sustainable financial profile through commercialization of zumilokibart

without need for future equity financing

Apogee to host webcast with the APEX Phase

2 Part B results today at 8:00 a.m. Eastern Time

San Francisco and Boston, May 27, 2026, (GLOBE

NEWSWIRE) — Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics

with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced that it has

entered into a strategic financing collaboration with funds managed by Blackstone Life Sciences (“Blackstone”) for up to

$1.3 billion in flexible, non-dilutive total capital to support the continued development and potential commercialization of zumilokibart.

“Our partnership with Blackstone Life Sciences

represents a major milestone in the advancement of zumilokibart as the next meaningful first line therapy for moderate-to-severe atopic

dermatitis,” said Michael Henderson, M.D., Chief Executive Officer of Apogee Therapeutics. “This collaboration provides non-dilutive

flexible funding at an attractive cost of capital for the late-stage development of zumilokibart and establishes a path to commercialization

and profitability for Apogee. As supported by our Apex Part B data announced today, we believe zumilokibart has the potential to be a

transformative therapy for patients with differentiated efficacy and dosing in atopic dermatitis and other large I&I indications.”

“We are excited to support Apogee's advancement

of zumilokibart through Phase 3 development and potential commercialization,” said Dr. Nicholas Galakatos, Global Head of Blackstone

Life Sciences. “Our collaboration with Apogee is a great example of our strategy to provide leading biotechnology companies with non-dilutive financing at scale and the resources and flexibility to further scientific innovation and invest in the advancement

of their pipelines."

Added Kiran Reddy, M.D., Senior Managing Director, Blackstone Life

Sciences, "This is the largest royalty financing for a pre-Phase 3 program to date. It reflects our conviction that zumilokibart

has the potential to become a highly differentiated, multi-indication product that will have a major impact on patients' quality of life."

Transaction Overview

The collaboration agreement provides for up to

$1.3 billion in flexible, non-dilutive total capital, including up to $800 million of synthetic royalty and up to $500 million of senior

debt available at the mutual consent of Apogee and Blackstone.

Synthetic royalty: Blackstone

will provide up to $800 million of synthetic royalty funding in exchange for low-to-mid single digit tiered royalties for a term of 15

years on worldwide annual sales of zumilokibart. The royalties decrease based on sales with no royalties on global annual sales in excess

of $8 billion.

· The

first $400 million in preapproval funding is divided into 3 tranches, including $100 million

at signing, $100 million upon completion of zumilokibart Phase 3 enrollment, and $200 million

upon positive Phase 3 data. Upon FDA approval of zumilokibart, up to $400 million in additional

funding is available, $150 million of which is at Apogee’s option

· The

funding agreement includes specific provisions on a change of control, with the option to

buy back a significant portion of the royalty.

· Senior

debt: Up to $500 million of senior corporate debt is available at mutual consent of Apogee

and Blackstone

Additional details regarding the funding agreement

can be found in the Current Report on Form 8-K filed by the company today with the U.S. Securities and Exchange Commission.

Cash runway update

As a result of entering into this funding agreement

with Blackstone, the company is removing its cash runway end date guidance.

Webcast Details

Apogee Therapeutics will hold a live webcast

to discuss the Blackstone transaction and the results of the APEX Phase 2 Part B trial today at 8:00 a.m. ET. The live webcast can be

accessed via this link or the Investors section on the company’s website at https://investors.apogeetherapeutics.com/news-events/events.

A replay of the webcast will be available following the call.

Advisors

Goldman Sachs served as exclusive financial

advisor and Latham & Watkins LLP as legal counsel to Apogee Therapeutics. Ropes & Gray LLP served as legal counsel to

Blackstone Life Sciences.

About Apogee

Apogee Therapeutics is a clinical-stage biotechnology

company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for

the treatment of AD, asthma, eosinophilic esophagitis (EoE), Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications.

Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms

of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart, the company’s

most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I

markets, as well as asthma and EoE. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy

and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company

believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information,

please visit https://apogeetherapeutics.com.

About Blackstone Life Sciences

Blackstone Life Sciences (BXLS) is a leading private investment platform

with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments

and hands-on operational leadership, BXLS helps bring to market promising new medicines and medical technologies that improve patients’

lives and currently has $17 billion in assets under management.

Forward Looking Statements

Certain statements in this press release may

constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to,

statements regarding Apogee’s expectations regarding: Apogee’s plans for its current and future product candidates, programs,

and clinical trials, including the Phase 3 development and potential commercialization of zumilokibart and expansion of zumilokibart

into additional indications; the potential clinical benefit, dosing regimen, safety and efficacy profiles and treatment outcomes of zumilokibart,

including its potential to be a best-in-class therapy, be the next meaningful first line therapy for AD, overcome limitations of existing

therapies, and be the new standard of care in AD; the potential for Apogee product candidates and programs to overcome limitations of

existing therapies; the potential of zumilokibart to become a differentiated, multi-indication product; its planned business strategies;

the financial resources available to Apogee, including the availability of capital from the synthetic royalty and potential debt arrangement

and whether Apogee achieves the milestones associated with certain payments thereunder and whether Apogee elects to receive optional

funding under the arrangement, if available; its expectations regarding the time period over which Apogee’s capital resources will

be sufficient to fund its anticipated operations, including its self-sustainable financial profile through commercialization of zumilokibart

without the need for future equity financing; its potential profitability; and estimates of market size. Words such as “may,”

“might,” “will,” “objective,” “intend,” “should,” “could,” “can,”

“would,” “expect,” “believe,” “design,” “estimate,” “predict,”

“potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements

regarding intent, belief, or current expectations, are forward-looking statements. While Apogee believes these forward-looking statements

are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available

to Apogee on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject

to various risks and uncertainties (including, without limitation, those set forth in Apogee’s filings with the U.S. Securities

and Exchange Commission (the SEC)), many of which are beyond Apogee’s control and subject to change. Actual results could be materially

different. Risks and uncertainties include: global macroeconomic conditions and related volatility, expectations regarding the initiation,

progress, and expected results of Apogee’s preclinical studies, clinical trials and research and development programs; expectations

regarding the timing, completion and outcome of Apogee’s clinical trials; the unpredictable relationship between preclinical study

results and clinical study results; the applicability of clinical study results to actual outcomes; the timing or likelihood of regulatory

filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in Apogee’s Annual Report

on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 2, 2026, and subsequent disclosure documents Apogee may

file with the SEC. Apogee claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995

for forward-looking statements. Apogee expressly disclaims any obligation to update or alter any statements whether as a result of new

information, future events or otherwise, except as required by law.

Apogee Investor Contact:

Noel Kurdi

VP, Investor Relations

Apogee Therapeutics, Inc.

Noel.Kurdi@apogeetherapeutics.com

Apogee Media Contact:

Dan Budwick

1AB Media

dan@1abmedia.com

Blackstone Life Sciences Media Contact:

David Vitek

(212) 583-5291

David.Vitek@blackstone.com

GRAPHIC

Filename: tm2615568d2_ex99-1img001.jpg · Sequence: 6

Binary file (4125 bytes)

Download tm2615568d2_ex99-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

May 26, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 26, 2026

Entity File Number

001-41740

Entity Registrant Name

Apogee

Therapeutics, Inc.

Entity Central Index Key

0001974640

Entity Tax Identification Number

93-4958665

Entity Incorporation, State or Country Code

Entity Address, Address Line One

221

Crescent Street

Entity Address, Address Line Two

Building 17

Entity Address, Address Line Three

Suite 102b

Entity Address, City or Town

Waltham

Entity Address, State or Province

Entity Address, Postal Zip Code

02453

City Area Code

650

Local Phone Number

394-5230

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.00001 per share

Trading Symbol

APGE

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration